Bottom Line: States that implemented medical marijuana laws appear to have lower annual opioid analgesic overdoses death rates (both from prescription pain killers and illicit drugs such as heroin) than states without such laws although the reason why is not clear.
Author: Marcus A. Bachhuber, M.D., of the Philadelphia Veterans Affairs Medical Center, and colleagues.
Background: Prescriptions for opioid painkillers for chronic pain have increased in the United States and so have overdose deaths. However, less attention has been focused on how the availability of alternative nonopioid treatment, such as medical marijuana, may affect overdose rates.
How the Study Was Conducted: The authors examined the implementation of state medical marijuana laws and opioid analgesic overdose deaths in the United States between 1999 and 2010. Three states had medical marijuana laws prior to 1999, 10 states implemented laws between 1999 and 2010 and nine states had laws that went into effect after 2010, which was beyond the study period. The authors also considered New Jersey's law effective after the study period because it took effect in the last quarter of 2010. The authors analyzed state laws and death-certificate data.
Results: States with medical marijuana laws had a 24.8 percent lower average annual opioid overdose death rate compared to states without such laws. In 2010, that translated to about 1,729 fewer deaths than expected. The years after implementation of medical marijuana laws also were associated with lower overdose death rates that generally got stronger over time: year 1 (-19.9 percent), year 2 (-25.2 percent), year 3 (-23.6 percent), year 4 (-20.2 percent), year 5 (-33.7 percent) and year 6 (-33.3 percent).
Discussion: "In summary, although we found a lower mean annual rate of opioid analgesic mortality in states with medical cannabis laws, a direct causal link cannot be established. ... If the relationship between medical cannabis laws and opioid analgesic overdose mortality is substantiated in further work, enactment of laws to allow for use of medical cannabis may be advocated as part of a comprehensive package of policies to reduce the population risk of opioid analgesics."
(JAMA Intern Med. Published online August 25, 2014. doi:10.1001/jamainternmed.2014.4005. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor's Note: An author made a conflict of interest disclosure. This work was funded by National Institutes of Health grants and the Center for AIDS Research at the Albert Einstein College of Medicine and Montefiore Medical Center. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Commentary: Legalization of Medical Marijuana and Incidence of Opioid Mortality
In a related commentary, Marie J. Hayes, Ph.D., of the University of Maine, Orno, and Mark S. Brown, M.D., of the Eastern Maine Medical Center, Bangor, write: "If medical marijuana laws afford a protective effect, it is not clear why. If the decline in opioid analgesic-related overdose deaths is explained, as claimed by the authors, by increased access to medical marijuana as an adjuvant medication for patients taking prescription opioids, does this mean that marijuana provides improved pain control that decreases opioid dosing to safer levels?"
"The potential protective role of medical marijuana in opioid analgesic-associated mortality and its implication for public policy is a fruitful area for future work," they conclude.
(JAMA Intern Med. Published online August 18, 2014. doi:10.1001/jamainternmed.2014.2716. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Media Advisory: To contact author Marcus A. Bachhuber, M.D., call Katie Delach at 215-349-5964 or email email@example.com. To contact commentary author Marie J. Hayes, Ph.D., call Margaret Nagle at 207-581-3745 or email firstname.lastname@example.org.
To place an electronic embedded link to this study in your story: Links for this study and commentary will be live at the embargo time: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2014.4005 and http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2014.2716.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.